Phathom Pharmaceuticals, Inc.
PHAT
|
$9.8
-2.29%
-2.35%
430K
|
Health Technology
(0.0% 1d) (13.7% 1m) (-8.6% 1y) (0.0% 2d) (-2.3% 3d) (-3.4% 7d) (-30.5% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 573,536,190
http://www.phathompharma.com
Sec Filling | Patents | 25 employees
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
gastrointestinal treatment
add to watch list Paper trade email alert is off
Press-releases
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: -0.31%
H: 2.35%
C: 0.92%
conference pharmaceuticals
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 2.3%
H: 6.7%
C: -1.78%
pharmaceuticals
SIGA Names Larry Miller General Counsel
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
SIGA | $8.51 -4.7% -4.94% 600K
|
Health Technology
|
| O: -7.42%
H: 5.73%
C: 2.96%
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 2.09%
H: 0.98%
C: -7.11%
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-07 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 7.81%
H: 0.67%
C: -13.35%
business year update pharmaceuticals financial results
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 0.83%
H: 2.67%
C: -1.56%
report business year update pharmaceuticals financial results
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: -2.82%
voquezna scripts express pharmaceuticals commercial
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 4.1%
H: 1.34%
C: -5.77%
conference pharmaceuticals
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
Published: 2023-12-14 (Crawled : 13:00) - globenewswire.com
HTGC F | $18.16 0.95% -0.22% 730K
|
Finance
|
| O: 0.9%
H: 2.57%
C: 1.08%
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 0.36%
H: 12.29%
C: 7.59%
security pharmaceuticals expansion agreement
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: -5.99%
voquezna fda drug treatment pharmaceuticals application
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
Published: 2023-11-28 (Crawled : 13:00) - globenewswire.com
PHAT | $9.8 -2.29% -2.35% 430K
|
Health Technology
|
| O: 0.42%
H: 3.86%
C: -1.1%
voquezna treatment pharmaceuticals commercial
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001395064-24-000008 | 4 | 2024-01-25 | 2024-01-24 | Sell | S | 3703703 | 3755583 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Last 48 Hours Insiders Buying
IZEA | $2.5 -2.4% 8.6K
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 1.05% 1.4M
|
Finance
|
22:30
CTRN P 18090 | $22.46 -1.01% -1.02% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.795 2.38% 0.18% 35K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 3.1M
|
Health Technology
|
16:30
RMCF | $3.51 -3.7% -3.85% 3.8K
|
Consumer Non-Durables
|
20:10